For the Inventor, By the Inventor

Enter assignee name

Wilmington, DE, United States of America

Incyte Corporation

Calculating rank

USPTO Granted Patents = 687

% Expired Patents = 11.5

CIPO Patents = 39

EPO Patents = 96

Trademarks = 7

Forward Citations = 10,457

Loading Chart...

Loading Chart...

392 inventors (with patents filed for the assignee):

Wenqing Yao (223 out of 228 patents)

Andrew Paul Combs (115 out of 129 patents)

Liangxing Wu (114 out of 114 patents)

4. Yun-Long Li (89 out of 96 patents)

5. Jincong Zhuo (71 out of 76 patents)

6. Chunhong He (71 out of 73 patents)

7. Jiacheng Zhou (63 out of 86 patents)

8. Richard B Sparks (63 out of 64 patents)

9. Eddy W Yue (63 out of 70 patents)

10. James David Rodgers (62 out of 86 patents)

11. Stacey Shepard (57 out of 59 patents)

12. Brian Walter Metcalf (55 out of 87 patents)

13. Xiaozhao Wang (49 out of 51 patents)

14. Ding-Quan Qian (49 out of 49 patents)

15. Zhongjiang Jia (48 out of 49 patents)

Core Competencies:

JAK Inhibitors

FGFR Inhibitors

KRAS Inhibitors

Immunomodulators

Tetracyclic Compounds

Tricyclic Compounds

Biomarkers

Combination Therapy

Pharmaceutical Formulations

PI3K Inhibitors

Anti-PD-1 Antibodies

Solid Forms

687 patents: Sort by Forward Citations

1. 12760022 - Tricyclic urea compounds as JAK2 V617F inhibitors (2026-10-13),

2. 12735424 - Fused pyrazine derivatives as A2A / A2B inhibitors (2026-09-15),

3. 12692276 - Tricyclic triazolo compounds as DGK inhibitors (2026-07-28),

4. 12643881 - BICYCLIC AMINE CDK12 INHIBITORS (2026-06-02),

5. 12642802 - Topical formulations of ruxolitinib with an organic amine pH adjusting agent for treatment of skin diseases (2026-06-02),

6. 12622908 - Topical formulation for a JAK inhibitor (2026-05-12),

7. 12600723 - Tetracyclic compounds as DGK inhibitors (2026-04-14),

8. 12600722 - Tetracyclic compounds as DGK inhibitors (2026-04-14),

9. 12600717 - Tricyclic compounds as inhibitors of KRAS (2026-04-14),

10. 12589096 - Ruxolitinib formulation for reduction of itch in atopic dermatitis (2026-03-31),

11. 12564593 - Topical formulation for a JAK inhibitor (2026-03-03),

12. 12552804 - TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS (2026-02-17),

13. 12552792 - SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME (2026-02-17),

14. 12551485 - Topical formulations of ruxolitinib with an organic amine pH adjusting agent for treatment of skin diseases (2026-02-17),

15. 12544381 - Topical formulation for JAK inhibitor (2026-02-10),

Company Overview

Incyte Corporation, headquartered in Wilmington, Delaware, is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company specializes in a range of therapeutic areas, particularly in oncology and hematology, with a strong emphasis on JAK inhibitors, FGFR inhibitors, and KRAS inhibitors. Incyte is also engaged in developing immunomodulators and various combination therapies, leveraging biomarkers to enhance treatment efficacy and patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

687 Patents

#12 in Wilmington, DE

#13 in Delaware

#735 in US

#1,457 in the World

Wilmington, DE, United States of America

Incyte Corporation

Forward Citations = 10,457

392 inventors:

Wenqing Yao (223 out of 228 patents)

Andrew Paul Combs (115 out of 129 patents)

Liangxing Wu (114 out of 114 patents)

4. Yun-Long Li (89 out of 96 patents)

5. Jincong Zhuo (71 out of 76 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Incyte Corporation. Retrieved from https://idiyas.com/company/incyte

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…